Literature DB >> 17907063

Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids.

Pedro A Orihuela1.   

Abstract

HRA Pharma, under license from the Research Triangle Institute, is developing ulipristal, a progesterone receptor modulator, for the potential use as a contraceptive and an emergency contraceptive, and for the potential treatment of uterine fibroids. Phase II clinical trials for uterine fibroids and phase III trials for contraception are underway. The drug was expected to be launched in the US and Europe in 2009.

Mesh：

Substances：

Year:  2007        PMID： 17907063

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

Review 1.  Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.

Authors:  Md Soriful Islam; Sadia Afrin; Sara Isabel Jones; James Segars
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

2.  Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies.

Authors:  Carsten Möller; Wilhelm Bone; Arwed Cleve; Ulrich Klar; Andrea Rotgeri; Antje Rottmann; Marcus-Hillert Schultze-Mosgau; Andrea Wagenfeld; Wolfgang Schwede
Journal:  ChemMedChem       Date:  2018-11-06       Impact factor: 3.466

3.  Combined experimental and quantum mechanical elucidation of the synthetically accessible stereoisomers of Hydroxyestradienone (HED), the starting material for vilaprisan synthesis.

Authors:  Tobias A Plöger; Stefan Koep; Hans-Christian Militzer; Andreas H Göller
Journal:  J Comput Aided Mol Des       Date:  2020-10-23       Impact factor: 3.686
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.